Portola Pharma (PTLA) Receives a Hold from Oppenheimer

By Ryan Adsit

Oppenheimer analyst Jay Olson maintained a Hold rating on Portola Pharma (PTLAResearch Report) yesterday and set a price target of $17.00. The company’s shares closed last Monday at $5.92, close to its 52-week low of $5.60.

According to TipRanks.com, Olson has 0 stars on 0-5 star ranking scale with an average return of -13.5% and a 29.5% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Enanta Pharmaceuticals.

Currently, the analyst consensus on Portola Pharma is a Moderate Buy with an average price target of $21.20, which is a 253.3% upside from current levels. In a report issued on March 2, Goldman Sachs also maintained a Hold rating on the stock with a $14.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $37.95 and a one-year low of $5.60. Currently, Portola Pharma has an average volume of 1.76M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.